'Superbug'-Fighting Pharma Firm Hits Ch. 11 With Sale Plans
Citing high costs and trouble getting drug candidates beyond the clinical phase, biopharmaceutical company Achaogen Inc. on Monday filed for Chapter 11 protection in Delaware, listing between $50 million and $100...To view the full article, register now.
Already a subscriber? Click here to view full article